Correspondence between Health Canada and the CCCA regarding concerns raised about the regulatory assessment and approval of COVID-19 mRNA vaccines

Correspondence between Health Canada and the CCCA regarding concerns raised about the regulatory assessment and approval of COVID-19 mRNA vaccines

In September 2022, members of the CCCA’s Scientific and Medical Advisory Committee (SMAC) sent a letter to Canada’s Minister of Health highlighting several fundamental flaws in Pfizer’s submission for approval of their COVID-19 genetic vaccine. The authors noted that these flaws were not identified in the regulatory assessment and they should have resulted in rejection of the submissions. A year later, a reply was received. On behalf of the CCCA, Dr. Steven Pelech, Co-Chair of SMAC, has sent a response addressing many inconsistencies between their answers in their reply and SMAC’s review of the literature and regulatory submissions. He requested a timely response to his questions as the modRNA products marketed as COVID-19 vaccines are increasingly being recognized as poorly, and even negatively efficacious, and the evidence of mounting harms from their usage continues to accumulate.

Share:

Facebook
Twitter
WhatsApp
LinkedIn

Related Posts